ABM Therapeutics

ABM Therapeutics is a clinical-stage biopharmaceutical company founded in 2015, focused on the discovery and development of small-molecule brain-penetrant targeted therapies for cancers of the central nervous system. The company's primary focus includes glioblastoma multiforme (GBM) and brain metastases originating from lung cancer, breast cancer, and melanoma, with a pipeline designed to address the historically underserved challenge of CNS drug penetration. ABM Therapeutics is headquartered in San Diego, California, led by co-founder and COO Charles Huang along with co-founder Chen Chen, and is advancing its lead clinical candidate ABM-1310 through Phase 1 trials with interim results presented at major oncology conferences including ASCO and AACR.